Top

BMC Cancer

Published in:

Open Access 01-12-2024 | Cytostatic Therapy | Research

Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer

Authors: Zheng-Jun Yang, Fei Xin, Zu-Jin Chen, Yue Yu, Xin Wang, Xu-Chen Cao

Published in: BMC Cancer | Issue 1/2024

Abstract

Background

Neoadjuvant chemotherapy with dual-targeted therapy is the standard treatment for human epidermal growth factor 2 (HER2)-positive breast cancer. Although the dual-targeted therapy has significantly improved the pathological complete response (pCR) rate, further investigation is needed to identify biomarkers that predict the response to neoadjuvant therapy.

Methods

This retrospective study analyzed 353 patients with HER2-positive breast invasive ductal carcinoma. The correlation between clinicopathological factors and pCR rate was evaluated. A nomogram was constructed based on the results of the multivariate logistic regression analysis to predict the probability of pCR.

Results

The breast pCR (b-pCR) rate was 56.1% (198/353) and the total pCR (t-pCR) rate was 52.7% (186/353). Multivariate analysis identified ER status, PR status, HER2 status, Ki-67 index, and neoadjuvant chemotherapy regimens as independent indicators for both b-pCR and t-pCR. The nomogram had an area under the receiver operating characteristic curve (AUC) of 0.73 (95% CI: 0.68–0.78). According to the nomogram, the t- pCR rate was highest in the ER-PR- HER2-positive patients (131/208) and lowest in the ER + PR + HER2-positive patients (19/73). The subgroup analyses showed that there was no significant difference in pCR rate among the neoadjuvant chemotherapy regimens in ER positive, PR positive, HER2 IHC 2 + , Ki67 index < 30% population. However, for ER-PR-HER2-positive patients, the neoadjuvant chemotherapy regimen has a great influence on the pCR rates.

Conclusions

Patients with ER-negative, PR-negative, HER2 3 + and high KI-67 index were more likely to achieve pCR. THP may be used as an alternative to AC-THP or TCbHP in selected HER2-positive patients.

Available only for authorised users

Yang ZJ, Liu YX, Huang Y, et al. The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score. Cancer Med. 2023;12(3):2493–504. https://doi.org/10.1002/cam4.5089.CrossRefPubMed

Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018;19(1):115–26. https://doi.org/10.1016/S1470-2045(17)30716-7.CrossRefPubMed

Masuda N, Ohtani S, Takano T, et al. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer. Breast Cancer Res Treat. 2020;180(1):135–46. https://doi.org/10.1007/s10549-020-05524-6.CrossRefPubMedPubMedCentral

Xiao Y, Ding J, Ma D, Chen S, Li X, Yu K. Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer. Front Immunol. 2022;13: 877825. https://doi.org/10.3389/fimmu.2022.877825.CrossRefPubMedPubMedCentral

Gonullu B, Angeli E, Pamoukdjian F, Bousquet G. HER2 Amplification Level Predicts Pathological Complete Response in the Neoadjuvant Setting of HER2-Overexpressing Breast Cancer: A Meta-Analysis and Systematic Review. Int J Mol Sci. Feb 10 2023;24(4)https://doi.org/10.3390/ijms24043590

Eijkelboom AH, de Munck L, Menke-van der Houven van Oordt CW, et al. Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study. Breast Cancer Res Treat. 2023;197(1):161–75. https://doi.org/10.1007/s10549-022-06732-y.CrossRefPubMed

Dieci MV, Griguolo G, Bottosso M, et al. Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy. NPJ Breast Cancer. 2021;7(1):101. https://doi.org/10.1038/s41523-021-00308-7.CrossRefPubMedPubMedCentral

Schettini F, Pascual T, Conte B, et al. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis. Cancer Treat Rev. 2020;84:101965. https://doi.org/10.1016/j.ctrv.2020.101965.CrossRefPubMedPubMedCentral

Dieci MV, Prat A, Tagliafico E, et al. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. Ann Oncol. 2016;27(10):1867–73. https://doi.org/10.1093/annonc/mdw262.CrossRefPubMed

10.

Prat A, Carey LA, Adamo B, et al. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J Natl Cancer Inst. Aug 2014;106(8)https://doi.org/10.1093/jnci/dju152

11.

Prat A, Bianchini G, Thomas M, et al. Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. Clin Cancer Res. 2014;20(2):511–21. https://doi.org/10.1158/1078-0432.CCR-13-0239.CrossRefPubMed

12.

Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. Oct 4 2012;490(7418):61–70. doi:https://doi.org/10.1038/nature11412

13.

Filho OM, Viale G, Stein S, et al. Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab. Cancer Discov. 2021;11(10):2474–87. https://doi.org/10.1158/2159-8290.CD-20-1557.CrossRefPubMedPubMedCentral

14.

Prat A, Pascual T, De Angelis C, et al. HER2-Enriched Subtype and erbb2 expression in HER2-positive breast cancer treated with dual HER2 Blockade. J Natl Cancer Inst. 2020;112(1):46–54. https://doi.org/10.1093/jnci/djz042.CrossRefPubMed

15.

Wang YC, Morrison G, Gillihan R, et al. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers–role of estrogen receptor and HER2 reactivation. Breast Cancer Res. 2011;13(6):R121. https://doi.org/10.1186/bcr3067.CrossRefPubMedPubMedCentral

16.

Giuliano M, Trivedi MV, Schiff R. Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: molecular basis and clinical implications. Breast Care (Basel). 2013;8(4):256–62. https://doi.org/10.1159/000354253.CrossRefPubMed

17.

Niu N, Qiu F, Xu Q, et al. A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer. Nat Commun. 2022;13(1):7043. https://doi.org/10.1038/s41467-022-34838-w.CrossRefPubMedPubMedCentral

18.

van Ramshorst MS, van der Voort A, van Werkhoven ED, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(12):1630–40. https://doi.org/10.1016/S1470-2045(18)30570-9.CrossRefPubMed

19.

Harbeck N. Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer. Breast. 2022;62(Suppl 1):S12–6. https://doi.org/10.1016/j.breast.2022.01.006.CrossRefPubMedPubMedCentral

20.

Schneeweiss A, Chia S, Hickish T, et al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer. 2018;89:27–35. https://doi.org/10.1016/j.ejca.2017.10.021.CrossRefPubMed

21.

Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278–84. https://doi.org/10.1093/annonc/mdt182.CrossRefPubMed

22.

Poggio F, Bruzzone M, Ceppi M, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018;29(7):1497–508. https://doi.org/10.1093/annonc/mdy127.CrossRefPubMed

23.

von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15(7):747–56. https://doi.org/10.1016/S1470-2045(14)70160-3.CrossRef

24.

Goldrick A, Olivotto IA, Alexander CS, et al. Anemia is a common but neglected complication of adjuvant chemotherapy for early breast cancer. Curr Oncol. 2007;14(6):227–33. https://doi.org/10.3747/co.2007.156.CrossRefPubMedPubMedCentral

25.

Leonard RC, Untch M, Von Koch F. Management of anaemia in patients with breast cancer: role of epoetin. Ann Oncol. 2005;16(5):817–24. https://doi.org/10.1093/annonc/mdi161.CrossRefPubMed

26.

Shen SJ, Liu CM. Chemotherapy for early-stage breast cancer: the more the better? Lancet. 2023;401(10384):1243–5. https://doi.org/10.1016/S0140-6736(23)00094-6.CrossRefPubMed

27.

Nitz UA, Gluz O, Christgen M, et al. De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel. Ann Oncol. 2017;28(11):2768–72. https://doi.org/10.1093/annonc/mdx494.CrossRefPubMed

28.

Harbeck N, Gluz O, Christgen M, et al. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early BC HER2- and hormone receptor-positive phase ii randomized trial-efficacy, safety, and predictive markers for 12 weeks of neoadjuvant trastuzumab emtansine with or without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. J Clin Oncol. 2017;35(26):3046–54. https://doi.org/10.1200/JCO.2016.71.9815.CrossRefPubMed

29.

Piccart MJ, Hilbers FS, Bliss JM, et al. Road map to safe and well-designed de-escalation trials of systemic adjuvant therapy for solid tumors. J Clin Oncol. 2020;38(34):4120–9. https://doi.org/10.1200/JCO.20.01382.CrossRefPubMed

30.

von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–28. https://doi.org/10.1056/NEJMoa1814017.CrossRef

31.

Zhou M, Wang S, Wan N, et al. Efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy regimen in Chinese patients with HER2-positive early breast cancer: a real-world retrospective multi-center cohort study. Ann Transl Med. 2022;10(24):1387. https://doi.org/10.21037/atm-22-6054.CrossRefPubMedPubMedCentral

32.

Mercogliano MF, Inurrigarro G, De Martino M, et al. Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer. BMC Cancer. 2017;17(1):895. https://doi.org/10.1186/s12885-017-3897-x.CrossRefPubMedPubMedCentral

33.

Bahreini F, Soltanian AR, Mehdipour P. A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer. Breast Cancer. 2015;22(6):615–25. https://doi.org/10.1007/s12282-014-0528-0.CrossRefPubMed

Title: Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
Authors: Zheng-Jun Yang
Fei Xin
Zu-Jin Chen
Yue Yu
Xin Wang
Xu-Chen Cao
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Cytostatic Therapy
Breast Cancer
Breast Cancer
Pertuzumab
Trastuzumab
Targeted Therapy
Published in: BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-024-11871-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Developing a risk assessment tool for cancer-related venous thrombosis in China: a modified Delphi-analytic hierarchy process study

Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study

Validation of primary and outcome data quality in a Swedish population-based breast cancer quality registry

Analysis of related factors for pathological upgrading of cervical biopsy from CIN3 to cancer after conical resection

Temporal trend in hospitalizations for malignant neoplasm and benign neoplasm: a nationwide study, China, 2004–2020

Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial

Keynote webinar | Spotlight on antibody–drug conjugates in cancer